Conexeu Sciences Advances Ten Minute Tissue™ Toward Planned FDA 510(k) Submission

What the company announced

Conexeu Sciences described progress across manufacturing, regulatory testing, and preclinical programs supporting a planned 510(k) submission for Ten Minute Tissue™. The company stated it remains on track to submit a 510(k) in the first calendar quarter of 2027 and reported that multiple scaled-up batches of CXU™ material met predefined Company specifications. The release frames manufacturing scale-up as a bridge between development-stage work and potential commercial production, and notes parallel workstreams intended to produce representative test material for regulatory studies.

Sources: S1

Regulatory and development activities reported

Conexeu listed concurrent workstreams the company is conducting to support a 510(k) filing: manufacturing process development and scale-up, production of regulatory test-material, preclinical wound-model studies, biocompatibility and product characterization testing, sterilization/packaging/stability testing, and FDA engagement via the Q-Submission process. The company said it is using representative test materials made with its controlled manufacturing process to support these activities.

Sources: S1

About Ten Minute Tissue™ and the CXU™ platform

The company describes Ten Minute Tissue™ as a thermosensitive extracellular matrix (ECM) that is fluid at room temperature and designed to transition to a stable gel in situ at body temperature within approximately ten minutes. Conexeu positions the CXU™ platform as intended to support soft tissue repair and lists preclinical characterizations including host cell infiltration, vascular ingrowth, organized remodeling, and a low-inflammatory profile. The release reiterates that Ten Minute Tissue™ is investigational and not FDA cleared or approved.

Sources: S1

Why this may matter (editorial inference)

If the reported manufacturing reproducibility and regulatory testing progress produce the data the company intends to include in a 510(k), Conexeu would be positioned to submit evidence for substantial equivalence to a predicate device as described. Establishing a controlled, scalable manufacturing process and representative test material can be material to preparing a 510(k) dossier and subsequent commercialization planning. These points are presented as company statements and reflect the potential regulatory and operational relevance of the described activities, not independent verification.

Sources: S1

What remains uncertain

• All factual program details are reported by the company; the release is issuer-provided and not independent verification.
• The device and the cited studies are preclinical; preclinical results are not necessarily predictive of clinical outcomes.
• A planned 510(k) submission and its timing are forward-looking statements and the FDA may not accept the submission, may request additional information, or may not grant clearance.
• Statements about future commercial manufacturing readiness and market opportunity are prospective and contingent on regulatory outcomes and other factors not established in the release.